Bioerg Spólka Akcyjna Past Earnings Performance
Past criteria checks 0/6
Bioerg Spólka Akcyjna's earnings have been declining at an average annual rate of -30.2%, while the Biotechs industry saw earnings growing at 56.3% annually. Revenues have been declining at an average rate of 10.6% per year.
Key information
-30.2%
Earnings growth rate
-30.2%
EPS growth rate
| Biotechs Industry Growth | 56.3% |
| Revenue growth rate | -10.6% |
| Return on equity | -29.3% |
| Net Margin | -22.1% |
| Next Earnings Update | 10 Aug 2023 |
Revenue & Expenses Breakdown
How Bioerg Spólka Akcyjna makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 0 | 0 | 0 | 0 |
| 30 Sep 22 | 1 | 0 | 1 | 0 |
| 30 Jun 22 | 1 | 0 | 1 | 0 |
| 31 Mar 22 | 1 | 0 | 1 | 0 |
| 31 Dec 21 | 2 | 0 | 1 | 0 |
| 30 Sep 21 | 5 | -13 | 5 | 0 |
| 30 Jun 21 | 9 | -13 | 7 | 0 |
| 31 Mar 21 | 11 | -13 | 8 | 0 |
| 31 Dec 20 | 10 | -12 | 8 | 0 |
| 30 Sep 20 | 11 | 1 | 8 | 0 |
| 30 Jun 20 | 13 | 1 | 9 | 0 |
| 31 Mar 20 | 14 | 0 | 10 | 0 |
| 31 Dec 19 | 16 | 0 | 13 | 0 |
| 30 Sep 19 | 16 | 0 | 12 | 0 |
| 30 Jun 19 | 14 | -1 | 12 | 0 |
| 31 Mar 19 | 11 | -1 | 9 | 0 |
| 31 Dec 18 | 8 | -1 | 7 | 0 |
| 30 Sep 18 | 5 | 0 | 4 | 0 |
| 30 Jun 18 | 1 | 0 | 1 | 0 |
| 31 Mar 18 | 0 | 0 | 0 | 0 |
| 31 Dec 17 | 0 | 0 | 0 | 0 |
| 30 Sep 17 | 0 | 0 | 0 | 0 |
| 30 Jun 17 | 0 | 0 | 0 | 0 |
| 31 Mar 17 | 0 | 0 | 0 | 0 |
| 31 Dec 16 | 0 | 0 | 0 | 0 |
| 30 Sep 16 | 2 | 0 | 0 | 0 |
| 30 Jun 16 | 2 | 0 | 0 | 0 |
| 31 Mar 16 | 2 | 0 | 0 | 0 |
| 31 Dec 15 | 2 | 0 | 0 | 0 |
| 30 Sep 15 | 1 | 0 | 0 | 0 |
| 30 Jun 15 | 1 | 0 | 0 | 0 |
| 31 Mar 15 | 2 | 0 | 0 | 0 |
| 31 Dec 14 | 2 | 0 | 0 | 0 |
| 30 Sep 14 | 2 | 0 | 0 | 0 |
| 30 Jun 14 | 2 | 0 | 0 | 0 |
| 31 Mar 14 | 3 | 0 | 1 | 0 |
| 31 Dec 13 | 2 | 0 | 1 | 0 |
| 30 Sep 13 | 2 | 0 | 1 | 0 |
| 30 Jun 13 | 2 | 0 | 1 | 0 |
| 31 Mar 13 | 2 | 0 | 1 | 0 |
| 31 Dec 12 | 2 | 0 | 0 | 0 |
| 30 Sep 12 | 1 | 0 | 1 | 0 |
| 30 Jun 12 | 1 | 0 | 0 | 0 |
Quality Earnings: BER is currently unprofitable.
Growing Profit Margin: BER is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BER is unprofitable, and losses have increased over the past 5 years at a rate of 30.2% per year.
Accelerating Growth: Unable to compare BER's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BER is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: BER has a negative Return on Equity (-29.33%), as it is currently unprofitable.